BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · IEX Real-Time Price · USD
161.28
+4.75 (3.03%)
May 2, 2024, 12:59 PM EDT - Market open
BeiGene Employees
BeiGene had 10,600 employees on December 31, 2023. The number of employees increased by 1,400 or 15.22% compared to the previous year.
Employees
10,600
Change (1Y)
1,400
Growth (1Y)
15.22%
Revenue / Employee
$231,960
Profits / Employee
-$83,180
Market Cap
17.12B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10,600 | 1,400 | 15.22% |
Dec 31, 2022 | 9,200 | 1,000 | 12.20% |
Dec 31, 2021 | 8,200 | 2,900 | 54.72% |
Dec 31, 2020 | 5,300 | 1,941 | 57.79% |
Dec 31, 2019 | 3,359 | 1,289 | 62.27% |
Dec 31, 2018 | 2,070 | 1,170 | 130.00% |
Dec 31, 2017 | 900 | 552 | 158.62% |
Dec 31, 2016 | 348 | 108 | 45.00% |
Dec 31, 2015 | 240 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Laboratory Corporation of America Holdings | 67,000 |
Quest Diagnostics | 48,000 |
Viatris | 38,000 |
Teva Pharmaceutical | 37,851 |
The Cooper Companies | 15,000 |
Hologic | 6,990 |
BioMarin Pharmaceutical | 3,401 |
BGNE News
- 6 days ago - BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report - Business Wire
- 7 days ago - Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting - Business Wire
- 9 days ago - BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer - Business Wire
- 6 weeks ago - BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - Business Wire
- 6 weeks ago - US FDA approves BeiGene's esophageal cancer therapy - Reuters
- 7 weeks ago - First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation - Business Wire
- 7 weeks ago - BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
- 7 weeks ago - US FDA approves expanded use of BeiGene's blood cancer drug - Reuters